TESARO (NASDAQ:TSRO)

CAPS Rating: 2 out of 5

Results 1 - 4 of 4

Recs

0
Member Avatar zzlangerhans (99.78) Submitted: 3/12/2016 7:13:34 PM : Underperform Start Price: $44.05 TSRO Score: +9.32

Before 2016, I didn't consider stocks for shorts unless I thought they were just ridiculously hopeless and overvalued. Now I've decided not to be helpless and shorts run wild over the biotech sector every other day. If you can't beat them, join them. I'm now starting shorts on biotechs that have stuck their heads up too far and made themselves attractive targets for snipers. One such candidate is Tesaro, which defied the market by bouncing back from a February low of 32 to as high as 47 in March without a material change in their long-term prospects. That brings the stock back to the recent high of 53 in December just before the bubble popped.

I suspect revenue numbers for the me-too antiemetic rolapitant will be disappointing when they are reported at the Q1 earnings call in May. At least one of the many competitors, Merck's Emend, is on the verge of having generic versions on the market. The PARP inhibitor niraparib is a little more of a wild card, with data from the NOVA and QUADRA phase III trials of niraparib in ovarian cancer expected in Q2. It seems like the pattern these days has been for phase II successes not to carry through to phase III. Even so, I'd prefer not to be holding this short through data. It's more of an insurance policy against the type of sessions where every biotech gets 5% slashed off its value for no better reason than the shorts like it that way. If you can't beat them, join them.

Recs

0
Member Avatar pchop123 (80.66) Submitted: 8/6/2014 4:43:11 PM : Outperform Start Price: $28.16 TSRO Score: +40.67

upside looks solid

Recs

0
Member Avatar IBDContrarian (47.78) Submitted: 11/30/2012 11:22:59 AM : Underperform Start Price: $18.30 TSRO Score: -81.83

IBD EPS, RS, SPROE, Acc ratings plus P/E and div yield
MEDICAL 1 97 ..A, NEG EARNINGS

Recs

0
Member Avatar orangeandblue2 (84.62) Submitted: 11/9/2012 6:21:09 PM : Outperform Start Price: $15.96 TSRO Score: +111.78

Jim Cramer approved spec play.

Results 1 - 4 of 4

Featured Broker Partners